Molecular radiotherapy developer Theragnostics and Summit Biomedical Imaging (SBI) have signed a licensing agreement to support the development of SBI's oral cancer detection technology.
The technology is intended to provide earlier diagnosis of cancer using the poly (ADP-ribose) polymerase (PARP) inhibitor PARPi-FL and fluorescence imaging in the oral cavity.
PARP activity and expression are upregulated in tumor cells. The inhibitor binds to PARP with a fluorescence tag, bringing the optical imaging agent to the cancer and enabling direct tumor detection, according to the companies.
